Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
219.89
+0.17 (0.08%)
At close: Oct 5, 2026, 4:00 PM EDT
222.36
+2.47 (1.12%)
Pre-market: Oct 6, 2026, 5:19 AM EDT
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 29 analysts polled by S&P Global, Alnylam Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $371.12. The average 1-year stock price forecast is 68.78% higher than the current stock price, while the lowest is $256 (+16.42%) and the highest is $536 (+143.76%).
Price Target: $371.12 (+68.78%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 15 | 14 | 14 | 16 | 16 |
| Buy | 6 | 7 | 7 | 8 | 7 | 6 |
| Hold | 8 | 8 | 8 | 6 | 6 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 28 | 30 | 29 | 28 | 29 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Maintains $325 | Hold | Maintains | $325 | +47.80% | Sep 30, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $375 → $369 | Buy | Reiterates | $375 → $369 | +67.81% | Sep 30, 2026 |
| Bernstein | Bernstein | Buy Maintains $376 | Buy | Maintains | $376 | +70.99% | Sep 26, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $455 | Buy | Reiterates | $455 | +106.92% | Sep 21, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $318 | Buy | Maintains | $318 | +44.62% | Sep 18, 2026 |
Financial Forecast
Revenue This Year
5.48B
from 3.71B
Increased by 47.60%
Revenue Next Year
6.94B
from 5.48B
Increased by 26.68%
EPS This Year
8.83
from 5.08
Increased by 73.90%
EPS Next Year
12.42
from 8.83
Increased by 40.62%
EPS and Forward PE are based on non-GAAP adjusted numbers.